Vanda Pharmaceuticals Files 8-K on Financials
Ticker: VNDA · Form: 8-K · Filed: Jul 31, 2024 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | 8-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: VNDA
TL;DR
Vanda Pharma dropped an 8-K on July 31st detailing their financial results. Check it for the latest numbers.
AI Summary
Vanda Pharmaceuticals Inc. filed an 8-K on July 31, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing provides an update on Vanda Pharmaceuticals' financial performance and condition, which is crucial information for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate or significant risks.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Registrant
- July 31, 2024 (date) — Date of Report
- 2200 Pennsylvania Avenue NW Suite 300E Washington DC 20037 (address) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
- December 31 (date) — Fiscal year end
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Vanda Pharmaceuticals Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on July 31, 2024.
Where are Vanda Pharmaceuticals Inc.'s principal executive offices located?
Vanda Pharmaceuticals Inc.'s principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037.
In which state was Vanda Pharmaceuticals Inc. incorporated?
Vanda Pharmaceuticals Inc. was incorporated in Delaware.
When does Vanda Pharmaceuticals Inc.'s fiscal year end?
Vanda Pharmaceuticals Inc.'s fiscal year ends on December 31.
Filing Stats: 1,008 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-07-31 16:05:32
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VNDA The Nasdaq Global Market
Filing Documents
- vnda-20240731.htm (8-K) — 36KB
- vnda8-k7312024exhibit991.htm (EX-99.1) — 132KB
- vandaq32019earningsca_imag.jpg (GRAPHIC) — 48KB
- 0001628280-24-033743.txt ( ) — 417KB
- vnda-20240731.xsd (EX-101.SCH) — 3KB
- vnda-20240731_def.xml (EX-101.DEF) — 16KB
- vnda-20240731_lab.xml (EX-101.LAB) — 28KB
- vnda-20240731_pre.xml (EX-101.PRE) — 16KB
- vnda-20240731_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On July 31, 2024, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release and is holding a conference call regarding its results of operations and financial condition for the quarter ended June 30, 2024 (the "Earnings Call"). The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. Various statements to be made during the Earnings Call are "forward-looking statements" under the securities laws, including, but not limited to, statements regarding Vanda's commercial products, plans and opportunities, as well as statements about Vanda's products in development and the related clinical development and regulatory timelines and commercial potential for such products. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding the strength of its business in the U.S. and Vanda's ability to complete the clinical development of, and obtain regulatory approval for, the products in its pipeline. Therefore, no assurance can be given that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements made during the Earnings Call should be evalua
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Vanda Pharmaceuticals Inc. dated July 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 31, 2024 VANDA PHARMACEUTICALS INC. By: /s/ Timothy Williams Name: Timothy Williams Title: Senior Vice President, General Counsel and Secretary